Headlands Technologies LLC Raises Stake in Galapagos NV (NASDAQ:GLPG)

Headlands Technologies LLC lifted its position in shares of Galapagos NV (NASDAQ:GLPG) by 56.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,233 shares of the biotechnology company’s stock after purchasing an additional 446 shares during the quarter. Headlands Technologies LLC’s holdings in Galapagos were worth $31,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of GLPG. Quadrant Capital Group LLC grew its holdings in shares of Galapagos by 18.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 261 shares during the period. Primecap Management Co. CA grew its holdings in shares of Galapagos by 1.4% during the 4th quarter. Primecap Management Co. CA now owns 678,877 shares of the biotechnology company’s stock worth $27,596,000 after purchasing an additional 9,200 shares during the period. Vestal Point Capital LP purchased a new stake in shares of Galapagos during the 4th quarter worth about $5,284,000. Barometer Capital Management Inc. purchased a new stake in shares of Galapagos during the 4th quarter worth about $122,000. Finally, Greenlight Capital Inc. boosted its holdings in Galapagos by 4.0% in the 4th quarter. Greenlight Capital Inc. now owns 162,578 shares of the biotechnology company’s stock worth $6,609,000 after acquiring an additional 6,200 shares during the period. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Analyst Upgrades and Downgrades

GLPG has been the subject of a number of analyst reports. Leerink Partnrs upgraded Galapagos to a “hold” rating in a report on Monday, September 9th. Leerink Partners initiated coverage on Galapagos in a report on Monday, September 9th. They issued a “market perform” rating and a $24.00 price target for the company. Finally, Raymond James cut Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. Based on data from MarketBeat.com, Galapagos has an average rating of “Hold” and a consensus target price of $31.00.

Galapagos Stock Down 0.4 %

Shares of GLPG opened at $30.56 on Wednesday. The business’s 50 day moving average is $27.01 and its two-hundred day moving average is $28.53. Galapagos NV has a 52-week low of $24.16 and a 52-week high of $42.46.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.